TWN Bookshop
Advanced Search
Your cart is empty

Unpacking the Issue of Counterfeit Medicines

Product 10/11

Previous
Return to the Product List
Next
USD 10.00 Publisher: TWN
ISBN: 978-967-5412-23-3
Year: 2010
No. of pages: 72
Size of book: 16.5cm x 24cm
Author: K.M. Gopakumar & Sangeeta Shashi
About the Book

Numerous anti-counterfeiting initiatives driven by an intellectual property enforcement agenda have emerged in international organisations.

The World Health Organisation has also accelerated action against ‘counterfeit medicines’, through the International Medical Product Anti-Counterfeit Taskforce (IMPACT). The WHO’s approach has resulted in concerns that legitimate generic medicines may get caught up in the web of definitions and enforcement of ‘counterfeit products’, with adverse consequences for access to medicine as well as legitimate trade.

This book discusses the background to the issue of ‘counterfeit medicines’ in the WHO as well as the problems of using the term ‘counterfeit’ (in connection with intellectual property rights violations) to refer to products with compromised quality, safety and efficacy issues against a background of anti-counterfeiting initiatives in the context of IP enforcement aggressively being pushed by businesses and governments of the Organisation for Economic Cooperation and Development (OECD).

The book also discusses origins of the IMPACT and analyses issues and concerns about the Taskforce pertaining to legitimacy, transparency, accountability, links to IP enforcement, and the creation of barriers to trade in, and access to, affordable generic medicines.


About the Author

DR K M GOPAKUMAR is a legal adviser to the Third World Network based in India.

SANGEETA SHASHIKANT is a legal adviser to the Third World Network.


Contents

Chapter 1. INTRODUCTION

Chapter 2. WHO AND COUNTERFEIT DRUGS

Chapter 3. ANTI-COUNTERFEITING INITIATIVES

3.1 G-8 Countries’ Initiatives on Counterfeits

3.2 Initiatives of the US Government

3.3 Initiatives of the European Union

3.4 World Customs Organisation

3.5 Interpol

3.6 World Intellectual Property Organisation

3.7 Anti-Counterfeiting Trade Agreement

3.8 Industry and the IP Enforcement

Chapter 4. INTERNATIONAL MEDICAL PRODUCT ANTI-COUNTERFEIT TASKFORCE

4.1 Establishment, Organisational Structure and Outcomes

4.2 IMPACT and the IP Enforcement Agenda

4.3 Participation, Transparency and Standard-Setting Activities

4.3.1 Participation

4.3.2 Transparency

4.3.3 Standard-Setting Activities

4.3.4 TRIPS-Plus Agenda

4.3.5 Non-Tariff Barriers: Undermining Generic Production and Parallel Trade

4.4. IMPACT: Faulty Approach

Chapter 5. COUNTERFEIT: MEANING AND DEFINITION

5.1 IFPMA-WHO Definition

5.2 IMPACT’s Definition of Counterfeit in 2007

5.3 IMPACT’s Definition of Counterfeit in 2008

5.4 Implications for Access to Medicines

Chapter 6. COUNTERFEIT AND PROBLEM OF DATA

Chapter 7. CONCLUSION

Annexure 

Add to Cart:


This product was added to our catalog on Wednesday 15 February, 2012.


| Home | About Us | Contact | Sitemap |

Copyright © 2011 Third World Network.      All Rights Reserved